Role of galectin‐3 in subclinical myocardial impairment in psoriasis

Background Psoriasis has been shown to increase cardiovascular risk, and a contributor to this might be enhanced myocardial fibrosis promoted by the disease‐associated pro‐inflammatory milieu. Objective We sought to investigate the relationship of galectin‐3 (Gal‐3) – a recognized mediator of fibros...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 33; no. 1; pp. 136 - 142
Main Authors Kotwica, T., Relewicz, J., Rojek, A., Tupikowska‐Marzec, M., Kabaj, M., Karolko, B., Maj, J., Bednarek‐Tupikowska, G., Kosmala, W., Szepietowski, J.C., Przewlocka‐Kosmala, M.
Format Journal Article
LanguageEnglish
Published England 01.01.2019
Subjects
Online AccessGet full text
ISSN0926-9959
1468-3083
1468-3083
DOI10.1111/jdv.15211

Cover

More Information
Summary:Background Psoriasis has been shown to increase cardiovascular risk, and a contributor to this might be enhanced myocardial fibrosis promoted by the disease‐associated pro‐inflammatory milieu. Objective We sought to investigate the relationship of galectin‐3 (Gal‐3) – a recognized mediator of fibrosis with inflammatory activation and left ventricular (LV) systolic and diastolic function in patients with psoriasis. Methods We enrolled 102 psoriatic patients (mean age: 52.5 ± 12.6 years). Sixty‐five age‐ and sex‐matched healthy subjects served as controls. Echocardiographic assessment of myocardial function included estimation of LV longitudinal systolic deformation (GLS) and diastolic indices: tissue e′ velocity and E/e′ ratio. Laboratory measurements encompassed blood Gal‐3, creatinine, glucose, insulin, CRP and erythrocyte sedimentation rate (ESR). Results Patients with psoriasis were characterized by elevated Gal‐3 (12.3 [9.3–13.4] vs. 6.3 [5.5–9.4] ng/mL in healthy controls, P < 0.001), ESR (17.0 [11.0–29.0] vs. 8.5 [6.0–13.0] mm, respectively, P < 0.001) and CRP (3.1 [1.7–10.6] vs. 1.9 [1.5–4.0] mg/L, respectively, P < 0.001), and reduced GLS (19.9 ± 3.7 vs. 22.0 ± 3.0%, respectively, P < 0.001). Progressive deterioration of GLS was demonstrated across Gal‐3 tertiles. Significant associations between GLS and age (beta = −0.21, P < 0.04), Gal‐3 (beta = −0.27, P < 0.01), CRP (beta = −0.22, P < 0.03), ESR (beta = −0.25, P < 0.01), waist circumference (beta = −0.22, P < 0.03) and waist‐to‐hip ratio (beta = −0.20, P < 0.05) were found. Stepwise multiple regression analysis revealed that the independent determinants of GLS in psoriatic patients were Gal‐3 (beta = −0.24, P < 0.01) and ESR (beta = −0.21, P < 0.03). Regression‐based mediation analysis demonstrated that the relationship between ESR and GLS was partially mediated by Gal‐3. Conclusions Subclinical left ventricular systolic dysfunction in psoriasis, as evidenced by reduced GLS, is linked with the inflammatory upregulation, and enhanced profibrotic activity (as reflected by elevated serum Gal‐3) may be involved in this process. These putative mechanisms may be responsible for the observed higher incidence of heart failure in this disease condition and should be considered as a potential target for preventive and therapeutic measures.
Bibliography:The authors declare no conflict of interests.
This work was financially supported by internal University grant Pbmn127.
Conflict of interests
Funding
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0926-9959
1468-3083
1468-3083
DOI:10.1111/jdv.15211